A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy Volunteer Human Challenge Model.
H3N2
challenge
healthy volunteer
influenza A
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
27 11 2019
27 11 2019
Historique:
received:
29
10
2018
accepted:
11
02
2019
pubmed:
17
2
2019
medline:
20
9
2020
entrez:
17
2
2019
Statut:
ppublish
Résumé
The development of vaccines and therapeutics has relied on healthy volunteer influenza challenge studies. A validated human infection model with wild-type A(H1N1)pdm09 was reported previously. Our objective was to characterize a wild-type influenza A/Bethesda/MM1/H3N2 challenge virus in healthy volunteers. Participants received a single dose of a cell-based, reverse-genetics, Good Manufacturing Practices-produced wild-type influenza A(H3N2)2011 virus intranasally and were isolated at the National Institutes of Health Clinical Center for ≥9 days. Dose escalation was performed from 104 to 107 TCID50 (50% tissue culture infectious dose). Viral shedding and clinical disease were evaluated daily. Of 37 participants challenged, 16 (43%) had viral shedding and 27 (73%) developed symptoms, with 12 (32%) participants experiencing mild to moderate influenza disease (MMID), defined as shedding and symptoms. Only participants receiving 106 and 107 TCID50 experienced MMID at 44% and 40%, respectively. Symptom severity peaked on day 3, whereas most viral shedding occurred 1-2 days after challenge. Only 10 (29%) participants had a ≥4-fold rise in hemagglutination inhibition antibody titer after challenge. The A/Bethesda/MM1/H3N2 challenge virus safely induced MMID in healthy volunteers, but caused less MMID than the A(H1N1)pdm09 challenge virus even at the highest dose. There was less detection of shedding though the incidence of symptoms was similar to A(H1N1)pdm09. Fewer serum anti-hemagglutinin (HA) antibody responses with less MMID indicate that preexisting immunity factors other than anti-HA antibody may limit shedding in healthy volunteers. This A/Bethesda/MM1/H3N2 challenge virus can be utilized in future studies to further explore pathogenesis and immunity and to evaluate vaccine candidates. NCT02594189.
Sections du résumé
BACKGROUND
The development of vaccines and therapeutics has relied on healthy volunteer influenza challenge studies. A validated human infection model with wild-type A(H1N1)pdm09 was reported previously. Our objective was to characterize a wild-type influenza A/Bethesda/MM1/H3N2 challenge virus in healthy volunteers.
METHODS
Participants received a single dose of a cell-based, reverse-genetics, Good Manufacturing Practices-produced wild-type influenza A(H3N2)2011 virus intranasally and were isolated at the National Institutes of Health Clinical Center for ≥9 days. Dose escalation was performed from 104 to 107 TCID50 (50% tissue culture infectious dose). Viral shedding and clinical disease were evaluated daily.
RESULTS
Of 37 participants challenged, 16 (43%) had viral shedding and 27 (73%) developed symptoms, with 12 (32%) participants experiencing mild to moderate influenza disease (MMID), defined as shedding and symptoms. Only participants receiving 106 and 107 TCID50 experienced MMID at 44% and 40%, respectively. Symptom severity peaked on day 3, whereas most viral shedding occurred 1-2 days after challenge. Only 10 (29%) participants had a ≥4-fold rise in hemagglutination inhibition antibody titer after challenge.
CONCLUSIONS
The A/Bethesda/MM1/H3N2 challenge virus safely induced MMID in healthy volunteers, but caused less MMID than the A(H1N1)pdm09 challenge virus even at the highest dose. There was less detection of shedding though the incidence of symptoms was similar to A(H1N1)pdm09. Fewer serum anti-hemagglutinin (HA) antibody responses with less MMID indicate that preexisting immunity factors other than anti-HA antibody may limit shedding in healthy volunteers. This A/Bethesda/MM1/H3N2 challenge virus can be utilized in future studies to further explore pathogenesis and immunity and to evaluate vaccine candidates.
CLINICAL TRIALS REGISTRATION
NCT02594189.
Identifiants
pubmed: 30770534
pii: 5321121
doi: 10.1093/cid/ciz141
pmc: PMC6880340
doi:
Substances chimiques
Antibodies, Viral
0
Influenza Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT02594189']
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2082-2090Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Références
J Infect Dis. 2018 Jul 2;218(3):347-354
pubmed: 29506129
J Virol. 2008 Jan;82(2):596-601
pubmed: 17942553
BMC Infect Dis. 2018 Jul 28;18(1):353
pubmed: 30055573
J Mol Biol. 2006 Feb 24;356(3):651-63
pubmed: 16384583
J Virol. 1988 Feb;62(2):488-95
pubmed: 3336068
Value Health. 2018 Feb;21(2):210-218
pubmed: 29477403
Lancet. 2009 May 9;373(9675):1645-53
pubmed: 19427959
Antiviral Res. 1989 Feb;11(1):27-40
pubmed: 2712549
MMWR Morb Mortal Wkly Rep. 2014 Jun 6;63(22):483-90
pubmed: 24898165
MMWR Morb Mortal Wkly Rep. 2017 Jun 30;66(25):668-676
pubmed: 28662019
Clin Infect Dis. 2015 Mar 1;60(5):693-702
pubmed: 25416753
MMWR Morb Mortal Wkly Rep. 2015 Jun 5;64(21):583-90
pubmed: 26042650
PLoS One. 2010 Jan 18;5(1):e8754
pubmed: 20090904
J Clin Microbiol. 1990 Mar;28(3):596-9
pubmed: 2182673
Infect Immun. 1982 Oct;38(1):141-6
pubmed: 7141686
Immunity. 2017 Oct 17;47(4):599-603
pubmed: 29045889
J Clin Microbiol. 1986 May;23(5):852-7
pubmed: 3711273
MMWR Morb Mortal Wkly Rep. 2016 Jun 10;65(22):567-75
pubmed: 27281364
Lancet. 1984 Mar 31;1(8379):705-8
pubmed: 6143042
PLoS One. 2018 Mar 22;13(3):e0194180
pubmed: 29566007
J Clin Microbiol. 1992 Mar;30(3):655-62
pubmed: 1551982
Br Med Bull. 1979 Jan;35(1):69-75
pubmed: 367490
J Virol. 2013 Aug;87(16):9290-300
pubmed: 23785204
J Med Virol. 1989 Feb;27(2):137-41
pubmed: 2921600
MBio. 2016 Apr 19;7(2):e00417-16
pubmed: 27094330
Vaccine. 1999 Dec 10;18(9-10):899-906
pubmed: 10580204
PLoS One. 2011;6(10):e26047
pubmed: 22039434
J Antimicrob Chemother. 1986 Jul;18(1):119-29
pubmed: 3531141
MBio. 2018 Jan 23;9(1):
pubmed: 29362240
Curr Protoc Immunol. 2001 May;Chapter 19:Unit 19.11
pubmed: 18432752
BMC Infect Dis. 2016 Jan 05;16:1
pubmed: 26729246
J Infect Dis. 1988 Dec;158(6):1209-19
pubmed: 3198936
Infect Immun. 1981 May;32(2):693-7
pubmed: 7251144
J Clin Microbiol. 1989 Jan;27(1):219-22
pubmed: 2913033
MMWR Morb Mortal Wkly Rep. 2018 Jun 08;67(22):634-642
pubmed: 29879098